<code id='65C28A1EF2'></code><style id='65C28A1EF2'></style>
    • <acronym id='65C28A1EF2'></acronym>
      <center id='65C28A1EF2'><center id='65C28A1EF2'><tfoot id='65C28A1EF2'></tfoot></center><abbr id='65C28A1EF2'><dir id='65C28A1EF2'><tfoot id='65C28A1EF2'></tfoot><noframes id='65C28A1EF2'>

    • <optgroup id='65C28A1EF2'><strike id='65C28A1EF2'><sup id='65C28A1EF2'></sup></strike><code id='65C28A1EF2'></code></optgroup>
        1. <b id='65C28A1EF2'><label id='65C28A1EF2'><select id='65C28A1EF2'><dt id='65C28A1EF2'><span id='65C28A1EF2'></span></dt></select></label></b><u id='65C28A1EF2'></u>
          <i id='65C28A1EF2'><strike id='65C28A1EF2'><tt id='65C28A1EF2'><pre id='65C28A1EF2'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:knowledge    Page View:11877
          Illumina Grail vertical merger
          Adobe

          SAN DIEGO — Months after announcing plans to cut costs by $100 million, DNA sequencing giant Illumina has begun to lay off 10% of its research and development team, according to internal emails obtained and reviewed by STAT.

          The layoffs, which began last Wednesday, impact research teams across the company’s California sites in San Diego and Foster City, as well as locations in Madison, Wisconsin; Singapore; and the United Kingdom. Alex Aravanis, the company’s chief technology officer, noted in an internal message that these cuts affect a tenth of research and development staff. The company’s also planning to shut down all lab-based research and development work in Foster City, according to a note from Steve Barnard, vice president of technology development.

          advertisement

          Barnard’s note mentions that all affected employees have already been notified. And a separate message from interim CEO Charles Dadswell makes clear last week’s layoffs won’t be the last.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          DIEP, the 'gold standard' of breast reconstruction, is under threat
          DIEP, the 'gold standard' of breast reconstruction, is under threat

          AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

          read more
          First U.S. drug developed to treat liver disease MASH is approved
          First U.S. drug developed to treat liver disease MASH is approved

          AdobeTheFoodandDrugAdministrationonThursdayapprovedthefirstmedicinedevelopedspecificallytotreatthese

          read more
          Peter Hotez and the public health issue of online harassment
          Peter Hotez and the public health issue of online harassment

          AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

          read more

          Hospitals warn Medicare's drug payment fix is ‘unlawful’

          AdobeHospitalsaretellinggovernmentofficialsitwouldbeillegaltoclawback$7.8billionaspartofaremedythati